Although circulating SFRP4 levels have been widely recognized as a novel biomarker of β-cell dysfunction, insulin resistance and other metabolic disorders, little is known about serum and EAT-derived SFRP4 expression in patients with CAD. Here, SFRP4 is linked to Insulin resistance.